Get the Stockscreener App
8.34
6.92%
-0.62
After Hours:
8.49
0.15
+1.80%
Zevra Therapeutics Inc stock is traded at $8.34, with a volume of 938.66K.
It is down -6.92% in the last 24 hours and up +2.08% over the past month.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
See More
Previous Close:
$8.96
Open:
$9
24h Volume:
938.66K
Relative Volume:
0.66
Market Cap:
$469.52M
Revenue:
$27.46M
Net Income/Loss:
$-46.05M
P/E Ratio:
-6.4651
EPS:
-1.29
Net Cash Flow:
$-33.83M
1W Performance:
-5.98%
1M Performance:
+2.08%
6M Performance:
-11.37%
1Y Performance:
-4.79%
1-Day Range:
$8.295
$9.02
1-Week Range:
$8.295
$9.02
52-Week Range:
$6.19
$13.16
Zevra Therapeutics Inc Stock (ZVRA) Company Profile
Name
Zevra Therapeutics Inc
Sector
Industry
Phone
(321) 939-3416
Address
1180 CELEBRATION BOULEVARD, SUITE 103, CELEBRATION
Compare ZVRA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ZVRA
Zevra Therapeutics Inc
|
8.34 | 504.43M | 27.46M | -46.05M | -33.83M | -1.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Zevra Therapeutics Inc Stock (ZVRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-02-25 | Initiated | H.C. Wainwright | Buy |
| Jan-08-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-07-24 | Initiated | Guggenheim | Buy |
| Sep-24-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-24-24 | Reiterated | Maxim Group | Buy |
| Apr-02-24 | Reiterated | Maxim Group | Buy |
| Mar-12-24 | Initiated | William Blair | Outperform |
| Mar-17-23 | Initiated | Maxim Group | Buy |
View All
Zevra Therapeutics Inc Stock (ZVRA) Latest News
Analysts’ Top Healthcare Picks: Ultragenyx Pharmaceutical (RARE), Zevra Therapeutics (ZVRA) - The Globe and Mail
Analysts Offer Insights on Healthcare Companies: Mereo Biopharma Group Plc (MREO) and Zevra Therapeutics (ZVRA) - The Globe and Mail
Zevra Therapeutics stock maintains Buy rating at H.C. Wainwright on expanded access deal - Investing.com UK
ZVRA Boosts Distribution for Miplyffa with Uniphar Agreement - GuruFocus
Zevra Therapeutics executes distribution agreement to broaden access to Miplyffa for the treatment of Niemann-Pick disease type C (NPC) - marketscreener.com
Zevra Therapeutics Signs Expanded Miplyffa Distribution Deal With Uniphar - marketscreener.com
Zevra Therapeutics (ZVRA) Expands MIPLYFFA Access with Uniphar A - GuruFocus
Zevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA® for the Treatment of Niemann-Pick Disease Type C (NPC) - The Manila Times
New deal expands access to a vital Niemann-Pick C treatment beyond Europe - Stock Titan
How Zevra Therapeutics Inc. (ZVRA) Affects Rotational Strategy Timing - Stock Traders Daily
Is Zevra Therapeutics Inc. stock a top pick in earnings seasonMarket Performance Report & Risk Controlled Swing Trade Alerts - bolumsonucanavari.com
Can Zevra Therapeutics Inc. stock double in next 5 years2025 Institutional Moves & Technical Pattern Recognition Alerts - Bölüm Sonu Canavarı
Profit Review: How institutional buying supports Zevra Therapeutics Inc. stockJuly 2025 Trends & Long-Term Growth Stock Strategies - Улправда
Analysts’ Top Healthcare Picks: Zevra Therapeutics (ZVRA), Novan (NOVN) - The Globe and Mail
Discipline and Rules-Based Execution in ZVRA Response - Stock Traders Daily
Is Zevra Therapeutics Attractively Priced After Recent Rare Disease Pipeline Progress? - Yahoo Finance
Is Zevra Therapeutics (ZVRA) Undervalued After Its Recent Share Price Pullback? - Yahoo Finance
Zevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
[Form 3] ZEVRA THERAPEUTICS, INC. Initial Statement of Beneficial Ownership - Stock Titan
Schroder Investment Management Group Acquires New Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics, Inc. $ZVRA Holdings Boosted by Stonepine Capital Management LLC - MarketBeat
Zevra Therapeutics Stock Drop Looks Sharp, But How Deep Can It Go? - Trefis
How Zevra Therapeutics Inc. stock performs after earningsPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Behavioral Patterns of ZVRA and Institutional Flows - Stock Traders Daily
Does Zevra Therapeutics’ (ZVRA) Board Turnover Subtly Recast Its Leadership and Capital Allocation Narrative? - simplywall.st
Why Zevra Therapeutics Inc. stock is favored by top institutionsDollar Strength & Stepwise Entry and Exit Trade Signals - Newser
Legal & General Group Plc Grows Stock Position in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics (ZVRA): Evaluating Valuation Following High-Profile Board Appointment and CFO Transition - simplywall.st
Zevra Therapeutics, Inc. Announces Director and Committee Changes, Effective as of December 2, 2025 - marketscreener.com
Zevra Therapeutics appoints Alicia Secor to board of directors; announces retirement of Wendy Dixon - marketscreener.com
Zevra Therapeutics Appoints Alicia Secor to Board - TipRanks
ZVRA FinancialsIncome Statement - Quiver Quantitative
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD - The Manila Times
Zevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors, Announces Retirement of Wendy Dixon - Quiver Quantitative
Zevra Therapeutics Announces Board Changes - TradingView — Track All Markets
Zevra Therapeutics (NasdaqGS: ZVRA) names Alicia Secor to board as Wendy Dixon, PhD, retires - Stock Titan
How Zevra Therapeutics Inc. (1GDA) stock valuation compares with sectorQuarterly Portfolio Report & Growth Focused Entry Reports - Newser
How Zevra Therapeutics Inc. (1GDA) stock expands through international marketsGDP Growth & Verified High Yield Trade Plans - Newser
How institutional buying supports Zevra Therapeutics Inc. stock - moha.gov.vn
Zevra Therapeutics (ZVRA): Assessing Valuation After CFO Succession News Spurs Fresh Investor Interest - simplywall.st
(ZVRA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Zevra Therapeutics CFO Resignation Announced - The Globe and Mail
Zevra Therapeutics announces CFO transition - MSN
Will Zevra Therapeutics Inc. (1GDA) stock issue positive guidanceGlobal Markets & Daily Technical Forecast Reports - newser.com
Why Zevra Therapeutics Inc. stock could rally in 2025July 2025 Analyst Calls & Safe Entry Point Alerts - newser.com
Zevra Therapeutics Announces CFO Transition - citybiz
Zevra Therapeutics (ZVRA) CFO to Step Down, Shares Fall - GuruFocus
Zevra Therapeutics, Inc. announces CFO transition - marketscreener.com
[8-K] ZEVRA THERAPEUTICS, INC. Reports Material Event | ZVRA SEC FilingForm 8-K - Stock Titan
Zevra Therapeutics Announces Departure of CFO R. LaDuane Clifton, Effective December 31, 2025 - Quiver Quantitative
Zevra Therapeutics Inc Stock (ZVRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):